These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11190527)

  • 1. [Monoclonal antibody SPan-1 in the diagnosis of exocrine pancreatic adenocarcinoma].
    Frena A; Mazziotti A; La Guardia G; Martin F
    Chir Ital; 2000; 52(4):369-77. PubMed ID: 11190527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
    Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker.
    Frena A
    Int J Biol Markers; 2001; 16(3):189-97. PubMed ID: 11605732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology.
    Märten A; Büchler MW; Werft W; Wente MN; Kirschfink M; Schmidt J
    J Immunother; 2010; 33(2):219-24. PubMed ID: 20139773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers in pancreatic cancer.
    Haglund C; Kuusela P; Roberts PJ
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
    Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
    Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
    Markocka-Maczka K
    Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
    Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
    Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
    Gold DV; Modrak DE; Ying Z; Cardillo TM; Sharkey RM; Goldenberg DM
    J Clin Oncol; 2006 Jan; 24(2):252-8. PubMed ID: 16344318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.